Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is an insulin analog presented as a solution for subcutaneous use. It lowers blood glucose in patients with type 1 or type 2 diabetes. It provides rapid onset of action, mimicking natural insulin secretion after meals, and is used as part of intensive insulin therapy regimens.

GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice, ensures product integrity during transport, and offers regulatory support for importers.

Insulin Aspart is a rapid‑acting insulin analog used to manage blood glucose in diabetes mellitus.

Type 1 diabetes mellitus: improves post‑prandial glucose control. Type 2 diabetes mellitus: used when oral agents are insufficient to achieve glycemic targets. Gestational diabetes mellitus: may be prescribed when insulin therapy is required during pregnancy.

Adverse reactions to Insulin Aspart may vary in frequency and severity.

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Weight gain: modest increase associated with improved glycemic control.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypoglycemia: prolonged low blood glucose that can lead to loss of consciousness. - Hypokalemia: low potassium levels, potentially serious if untreated. - Allergic edema: swelling of tissues due to hypersensitivity. - Serum sickness: immune complex–mediated reaction presenting with fever and rash. - Acute insulin allergy: immediate hypersensitivity to the insulin molecule.

When using Insulin Aspart, consider the following precautions.

Dose adjustment: tailor dose based on blood glucose monitoring and carbohydrate intake. Hypoglycemia risk: educate patients on signs and corrective measures. Renal impairment: monitor closely as clearance may be reduced. Pregnancy and lactation: use only if benefits outweigh risks. Drug interactions: review concomitant medications that affect glucose. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart may interact with several medicines; awareness of interaction severity helps guide monitoring.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms. - Concurrent use of sulfonylureas: increased risk of severe hypoglycemia. - Alcohol: can potentiate hypoglycemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity. - Corticosteroids: may raise glucose levels, requiring dose adjustment. - Thyroid hormones: may alter insulin requirements.